ArticleInternational ophthalmology2026
Risk stratification of visual field progression in optic disc drusen with and without glaucoma.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the visual field (VF) progression in patients with optic disc drusen (ODD) with or without glaucoma and identify factors associated with rapid deterioration.
methodsIn this single-center retrospective cohort, adult patients with ODD, ≥ 12 months of follow-up, and ≥ 3 reliable standard automated perimetry tests were included. VF progression was quantified as the VF mean deviation (MD) slope (dB/year) using linear mixed-effects modeling. Eyes were categorized as slow progression (MD slope > - 0.5 dB/year) or moderate-fast progression (MD ≤ - 0.5 dB/year). Baseline RNFL thickness and VF MD, Visual acuity, intraocular pressure (IOP), glaucoma diagnosis, and number of IOP-lowering medications (NOM) were extracted from the medical record. Associations with moderate-fast progression were evaluated using logistic regression.
resultsA total of 139 eyes from 84 patients were included (mean follow-up 57.4 ± 42.6 months; mean 4.9 perimetry tests/eye). Glaucoma was diagnosed in 83/139 eyes (59.7%). Overall, 91/139 eyes (65.5%) demonstrated VF deterioration (MD slope < 0 dB/year), more frequently in glaucoma-labeled eyes than no-glaucoma eyes (64/83 [77.1%] vs. 27/56 [48.2%]; p < 0.001). Moderate-fast progression occurred in 32/139 eyes (23.0%) and did not differ significantly by glaucoma status (28.9% vs. 14.3%, p = 0.064). In multivariable modeling, higher mean NOM was associated with higher odds of moderate-fast progression (adjusted odds ratio 2.41; 95% CI 1.06-5.45; p = 0.034), whereas glaucoma diagnosis and mean IOP were not independently associated. Severity-stratified analyses showed higher moderate-fast progression with baseline VF MD ≤ -6 dB (34.9% vs. 13.2%, p = 0.004) and RNFL < 80 µm (36.4% vs. 7.0%, p < 0.001).
conclusionsIn eyes with ODD, thinner RNFL and worse VF MD at baseline are associated with a higher risk of moderate-fast VF decline, supporting risk-stratified monitoring regardless of glaucoma label or IOP.
Indexed as
Identifiers
42802267What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.